Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for STIVARGA
- Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC)
- Regorafenib Plus Raltitrexed as Third-line Treatment in Advanced Colorectal Cancer Patients.
- Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy
- Adjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial
- ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST
- A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer
- Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation
- Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer
- The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs
- RegoNivo vs Standard of Care Chemotherapy in AGOC
- T-Cell Therapy (ECT204) in Adults With Advanced HCC
- Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer
- Optimization for Regorafenib in HCC
- Sequences Of REGorafenib And Trifluridine/Tipiracil in Patients With Metastatic Colorectal Cancer
- Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer
- Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib
- Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable)
- Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer
- Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas
- Regorafenib and XELOX as 2nd Line Treatment in Metastatic Colorectal Cancer
- Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer
- A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
- JS001 Combined With Regorafenib in Patients With Advanced Colorectal Cancer
- Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated in Patients With Previously Treated Metastatic Colorectal Cancer
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
- Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer
- Phase II Study of Regorafenib as Maintenance Therapy
- Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal Adenocarcinomas
- Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer
- Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer
- Study Maintenance Regorafenib vs Placebo, no Progression Patients After I Line Chemotherapy Metastatic Gastric Cancer
- Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer
- (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
- Apatinib Treatment as the Neoadjuvant Therapy in Advanced Colorectal Cancer
- Regorafenib in Combination With TAS-102 in Subjects With Metastatic Colorectal Cancer Who Have Progressed After Standard Therapy
- Study of Regorafenib in Patients With Advanced Myeloid Malignancies
- Ethyl Icosapentate and Physical Activity in Treating Fatigue in Patients With Advanced Cancer
- Regorafenib in Relapsed Glioblastoma
- The Drug Rediscovery Protocol (DRUP Trial)
- Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations
- A Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer
- Use of Regorafenib in Recurrent Epithelial Ovarian Cancer
- TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer
- A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer
- Stivarga Real Life Evidence in Hungary
- Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST
- Regorafenib in GIST With Secondary C-KIT Exon 17 Mutation
- Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma
- Efficacy of Ginseng for Patients on Regorafenib
- Study of Regorafenib and Sildenafil for Advanced Solid Tumors
- Regorafenib in Metastatic Colorectal Cancer
- Effects of LBM and PPIs on Pharmacokinetics and Safety of Regorafenib (BAY 73-4506) in Cancer Patients
- Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX
- A Biomarker Study in Patients Getting Regorafenib for Metastatic Colorectal Cancer
- A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas
- Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer
- Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer
- Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer
- Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy
- Oral Steroids for Regorafenib-induced Fatigue/Malaise in Unresectable mCRC (KSCC1402/HGCSG1402)
- Regorafenib in Reducing Recurrence in Patients With Non-metastatic Rectal Cancer Who Have Completed Curative-Intent Treatment
- Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors
- Regorafenib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction Who Have Completed Chemoradiation Therapy and Surgery
- Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases
- [18F]FLT-PET as a Predictive Imaging Biomaker of Treatment Responses to Regorafenib
- Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer
- Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST
- Single Agent Regorafenib in Refractory Advanced Biliary Cancers
- Stivarga Regulatory Post-Marketing Surveillance Study in Korea
- A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer
- Regorafenib and Cetuximab in Patients With Advanced Malignancy
- A Study of Regorafenib in Advanced Pancreatic Cancer Patients
- A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy
- Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma
- A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer
- Investigating the Use of Regorafenib (Stivarga®) in Patients With Metastatic Colorectal Cancer (mCRC) After Failure of Standard Therapy
- Regorafenib Post-marketing Surveillance in Japan
- Phase II Study of Regorafenib in Metastatic Soft Tissue Sarcoma
- Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer
- Regorafenib Post-marketing Surveillance
- Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor
Clinical trials list
click for details